1. Takeda announced positive results in a Phase 2 study of TAK-279, an oral, once-daily TYK2 inhibitor, in people with moderate to severe plaque psoriasis.Business Wire
  2. In retrospect, we say this was a bargain. Takeda reveals first data from $4 billion autoimmune disease pillThe Boston Globe
  3. Tada’s $4 billion Psoriasis pill helps clear skin in mid-stage study.Bloomberg
  4. Takeda raised by BofA to buy on growth prospects and debt repayment (NYSE:TAK)Seeking Alpha
  5. See full coverage on Google News

ودجت أحدث المقالات للصفحة الرئيسية تظهر على الصفحة الرئيسية فقط


Leave a Reply

Your email address will not be published. Required fields are marked *